Heidelberg Pharma announces financial figures for fiscal year 2018 and provides business update
- Key milestones reached for GMP manufacturing of HDP-101
- Preparation of the clinical trial with HDP-101 advanced
- Licensing partnerships to develop Antibody Targeted Amanitin Conjugates with agenta and Takeda making progress
- Phase III trial submitted and started by collaboration partner Telix
- Significant year-over-year revenue growth
- Conference call to be held on 21 March 2019 at 3:00 p.m. CET
Heidelberg Pharma AG today published its financial results and annual report for fiscal year 2018 (1 December 2017 – 30 November 2018) and its outlook for 2019.